JAMA Clinical Reviews JAMA Network

Approximately 3 million people in the US have heart failure with preserved ejection fraction (HFpEF). JAMA Executive Editor Gregory Curfman, MD, discusses diagnosis and treatment of HFpEF with authors Margaret Redfield, MD, and Barry Borlaug, MD, both from Mayo Foundation for Medical Education and Research Division of Cardiovascular Diseases.

Related Content:
Heart Failure With Preserved Ejection Fraction

More than 2 million individuals in the US are chronically infected with hepatitis C, and nearly 15 000 die every year. Antivirals are available but are not reaching the majority of infected individuals. In this Q&A, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Francis S. Collins, MD, PhD, discuss a plan to eliminate hepatitis C included in the Biden-Harris 2024 budget proposal.

Related Content:
A National Hepatitis C Elimination Program in the United States Eliminating Hepatitis C in the United States Former NIH Director Francis S. Collins on the New White House Plan to Eliminate Hepatitis C Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C After 12 Years, NIH Director Francis S. Collins, MD, PhD, Seeks His Next Chapter After 12 Years, NIH Director Francis S. Collins Seeks His Next Chapter

In January 2023, the US Organ Procurement & Transplantation Network (OPTN) required transplant centers to modify transplant list wait times for Black patients. JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and L. Ebony Boulware, MD, MPH, Dinushika Mohottige, MD, MPH, and Tanjala S. Purnell, PhD, MPH, discuss why the OPTN mandate is a valuable model for reforming race-based practices.

Related Content:
Race-Neutral Estimates of Kidney Function: Enhancing Equity Race-Based Equations Delayed Black Patients From Getting Onto Kidney Transplant Lists—An Unprecedented New Policy Seeks to Undo the Damage Redressing the Harms of Race-Based Kidney Function Estimation

Malignant primary brain tumors cause more than 15 000 deaths annually in the US. JAMA Fishbein Fellow Revital Marcus, MD, interviews Ingo Mellinghoff, MD, PhD, neuro-oncologist and chair of the department of neurology at Memorial Sloan Kettering Cancer Center in New York, about the epidemiology, diagnosis, and treatment of various primary malignant brain tumors in adults.

Related Content:
Glioblastoma and Other Primary Brain Malignancies in Adults

During the transition to menopause, approximately 50%-75% of individuals experience vasomotor or genitourinary symptoms. JAMA Senior Editor Linda Brubaker, MD, and Carolyn Crandall MD, MS, of the University of California, Los Angeles, discuss hormonal and nonhormonal therapy for treatment of menopausal symptoms.

Related Content:
Management of Menopausal Symptoms

Interview with Vanessa Northington Gamble, MD, PhD, author of Dr Herman A. Barnett, Black Civil Rights Activists, and the Desegregation of The University of Texas Medical Branch in 1949: “We Ought to Go in Texas and I Don’t Mean to a Segregated Medical School.” Hosted by Robert Steinbrook, MD, and Raegan W. Durant, MD, MPH.

Related Content:
Dr Herman A. Barnett, Black Civil Rights Activists, and the Desegregation of The University of Texas Medical Branch in 1949